Ann: SIRFLOX ASCO Abstract Released, page-111

First 111 Last

Share
Profile

Follow
cafa

8,917 Posts.

32

23/05/15

22:55

Post #: 15339093
Share

Originally posted by wg159 ↑

I would assume if they already had a significant OS result they would be required to present it, even though it was not a prescribed end point of the study. It would quickly become the standard first line. We can dream... It would also have likely been included in the abstract if this were so. I believe it is safe to assume it is insignificant with the current data. Insignificant data will still be very interesting if they present it and it shows improvement even at a significant level.

I would love to see OS + 4.8 months with a HR>0.6 with a p<0.1, that would indicate to me a very likely scenario for a successful FOXFIRE. But this goes both ways.... my guess, they'll wait for FOXFIRE.

Thanks Cafa, it was '35% for mCRC and about 30% for HCC', therefore I would assume off label usage of 35%. Although i'm still not 100% sure on the off label uses. Is this for other cancers? RCC- Kidney cancer? Or off label early liver treatments?
Also I think I might hold off calling them for a few weeks, I can wait, ASCO can not.

6186mark, yes sales and marketing is important but I feel like Sirtex are clearly gunning to become the standard of care. Meaning oncologists must prescribe sir-spheres or risk being negligent.

Expand

WG
65% Is off label, not 35%

35% is mCRC. However very little is 1 St line

SRX Price at posting: $27.55 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive

HotCopper Highlights: Your most watched and most discussed stocks this week

Trump Victory Sends Bitcoin Surging Above $75K – Is $100K Next?

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

IMU

Imugene kicks off Australian trial for blood cancer treatment

UBI

Universal Biosensors flat despite fresh deal with US medical product distributor

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

FG1

Flynn Gold reaches milestone exploration target for Golden Ridge

Trump is President Again: What Does This Mean for Crypto?

MMI

Metro Mining inks bauxite offtake contracts into 2026 with Chinese m